12 results about "Thrombolysis" patented technology

This invention relates to a pharmaceutical composition and its application for treating acute ischemic stroke. The pharmaceutical composition for treating acute ischemic stroke comprises separately packaged tissue-type plasminogen activator citPA5 and a platelet aggregation inhibitor. Its beneficial effects include significantly improving cerebral blood flow recovery, shortening thrombolysis time, reducing infarct volume, and improving neurological function without increasing the risk of bleeding, demonstrating a good synergistic thrombolytic effect.

The application discloses a sports nutrition food composition for blood vessel health and post-exercise recovery. Each 40g contains soybean protein isolate, whey protein, resistant dextrin, inulin, ginkgo biloba extract, hawthorn extract, grape seed extract, sea buckthorn peptide, natto powder (containing natto kinase), coenzyme Q10, natural vitamin E, vitamin C, bacillus subtilis DE111 and mineral probiotic premix. The application realizes blood vessel cleaning and post-exercise recovery through the synergy of multiple pathways such as direct thrombolytic effect of natto kinase, anti-platelet aggregation of ginkgo biloba / hawthorn / grape seed, protection of blood vessel endothelium by coenzyme Q10 / VE / VC, and regulation of intestinal tract by bacillus subtilis DE111. In-vitro thrombolysis experiment shows that the composition has clear fibrinolytic activity. All components meet the national standard of sports nutrition food, are safe and compliant, and are suitable for people with thrombosis risk and people who need blood vessel repair after high-intensity exercise.

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels. 20 24 20 26 17 22 A pr 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 6 1 7 2 2 A p r 2 0 2 4

This invention discloses a traditional Chinese medicine (TCM) for treating neck, back, and leg pain, as well as cardiovascular and cerebrovascular diseases, and its preparation method, belonging to the field of TCM technology. The TCM is composed of various medicinal herbs, including peach kernel, safflower, angelica, red peony root, leech, and earthworm, in specific weight proportions. Its core treatment principle is "activating blood circulation and removing blood stasis, clearing the meridians, promoting qi circulation and relieving pain, and dissolving thrombi and unblocking collaterals," while also addressing the symptoms by tonifying qi and blood and nourishing the liver and kidneys. The herbs work synergistically to treat both the root cause and the symptoms. The preparation method includes steps such as raw material screening and processing, ingredient mixing, decoction extraction, secondary decoction, flavoring, and packaging and storage. The process is simple and low-cost. This TCM has definite efficacy and few side effects, effectively treating injuries from falls and blows, lumbar muscle strain, lumbar disc herniation, cerebral infarction, cerebral hemorrhage, and myocardial infarction. It also improves symptoms such as limb numbness and hemiplegia, solving the problems of limited treatment scope and unstable efficacy in existing TCM formulas, making it suitable for clinical application.

This invention relates to the field of medical device technology, specifically disclosing a thrombus interceptor, comprising a support bladder and a connecting tube. The support bladder has a placement hole and multiple flow holes, the flow holes for blood flow, and the placement holes for accommodating a catheter. The support bladder can abut against the inner wall of a blood vessel after inflating. The connecting tube communicates with the support bladder and can be connected to an external machine to inflate or deflate the support bladder. Contrast agent can be filled into the support bladder. This solution, by using a thrombolytic catheter in conjunction with the interceptor, integrates thrombolysis, thrombectomy, and thrombus interception functions using ultrasound technology. This solves the problems of using metal filters for thrombus interception in existing technologies and enables timely treatment of thrombus patients even in remote areas with limited medical resources.

This invention discloses a biomarker for early diagnosis, assessment of disease progression, and prognostic evaluation in patients undergoing intravenous thrombolysis for acute ischemic stroke: Syndecan-1 in peripheral blood. This invention provides the application of a substance for detecting Syndecan-1 in peripheral blood in the preparation of products for early diagnosis of prognosis in patients undergoing intravenous thrombolysis for acute ischemic stroke; or in the preparation of products for assessing disease progression in patients undergoing intravenous thrombolysis for acute ischemic stroke; or in the preparation of products for assessing the prognosis of patients undergoing intravenous thrombolysis for acute ischemic stroke. Research results indicate that plasma Syndecan-1 levels represent a novel and independent prognostic biomarker that can improve the current risk stratification of patients undergoing intravenous thrombolysis for acute ischemic stroke. Blood tests are easily accepted by patients and can serve as an effective means for early diagnosis, assessment of disease progression, and prognostic evaluation in patients undergoing intravenous thrombolysis for acute ischemic stroke.

This invention relates to the field of minimally invasive interventional device technology, and particularly to a thrombectomy head and a magnetically controlled microrobot. The thrombectomy head includes a drilling section at the front end and a milling cutting edge connected to the rear end of the drilling section. The milling cutting edge includes at least two milling cutting edge structures, with a chip removal groove between adjacent milling cutting edge structures. This invention achieves graded thrombolysis by combining the drilling section and the milling cutting edge, first breaking up the fragments and then finely grinding them. Combined with the chip removal groove as a chip removal and guiding structure, this improves thrombus removal efficiency while allowing the finely milled small-molecule thrombus fragments to be quickly guided outwards along the chip removal groove with the blood flow. This effectively prevents fragments from accumulating and adhering at the cutting edge, causing head blockage and jamming, and continuously ensuring smooth fluid flow in the cutting area. This further reduces the risk of thrombus fragments re-aggregating and adhering to the blood vessel wall, leading to recurrent embolism, significantly improving thrombolysis smoothness and overall removal efficiency, and further enhancing safety.

A method for using metastable perfluorocarbon nanodroplets for ultrasonic lysis of blood clots includes administering metastable perfluorocarbon nanodroplets into a blood vessel that includes or that leads to a blood vessel that includes a blood clot, the metastable perfluorocarbon nanodroplets each have a liquid core comprising a perfluorocarbon material that has a boiling point below 25° C. at atmospheric pressure and that remains stable in liquid form at 25° C. at atmospheric pressure. The method further includes applying ultrasound energy to the perfluorocarbon nanodroplets within or surrounding the blood clot, causing the perfluorocarbon nanodroplets to vaporize and convert to bubbles, which cavitate and lyse the blood clot.

This invention discloses a filter-combined inferior vena cava stent, relating to the field of medical device technology. The stent includes a restraint end and an adjustment end connected to its two ends. A rotating structure for unblocking thrombi is connected between the restraint end and the adjustment end. The adjustment end also includes an adjustment structure for adjusting the mesh size of the adjustment end. This invention can aggregate and unblock thrombi, improving thrombolysis capacity, and can also personalize the mesh size of the filter according to the different blood vessel sizes of different patients.

A configuration method of a mobile ischemic stroke thrombolysis system, the configuration method comprising the following steps: setting respective operation functions according to the characteristics of respective functional components of the mobile ischemic stroke thrombolysis system; building a data transmission network between the functional components to realize transmission and interaction of data parameters; collecting a plurality of parameters of a patient in combination with the calculation results of the operation functions to preliminarily judge the basic information and specific condition of the patient; and summarizing statistical analysis in the mobile ischemic stroke thrombolysis system to generate a processing opinion to obtain a corresponding treatment scheme according to the specific condition of the patient.

The invention discloses a recombinant engineering bacterium, a preparation method thereof and application of the recombinant engineering bacterium in preparation of antithrombotic drugs, and belongs to the technical field of biological medicines. The recombinant engineering bacterium is prepared by taking salmonella typhimurium with relA and spoT gene mutations as a carrier and introducing a recombinant plasmid containing a thrombolytic enzyme coding gene into the carrier. The invention provides a recombinant engineering bacterium with biological safety, the recombinant engineering bacterium has high thrombus targeting property under a dynamic blood flow condition, various thrombus models can be specifically targeted, and the concentration of the recombinant engineering bacterium in thrombus tissues can reach more than ten thousand times of the concentration of normal tissues such as spleen, liver and the like through bacterium proliferation. Through mediated thrombus targeted therapy, thrombus can be effectively dissolved, and revascularization is achieved. The invention provides a more effective and safer treatment strategy for diseases caused by thrombus, such as myocardial infarction, cerebral apoplexy, pulmonary embolism and the like.

The application discloses a preparation method and application of a composition with antioxidation, thrombolytic, lipid-lowering and auxiliary blood vessel reconstruction effects, and relates to the technical field of functional compositions. The composition with the antioxidation, thrombolytic, lipid-lowering and auxiliary blood vessel reconstruction effects is characterized by being prepared from the following raw materials in parts by weight: 15-45 parts of red rice powder, 5-25 parts of natto kinase, 5-20 parts of chitosan oligosaccharide, 5-20 parts of fish collagen peptide, 0.5-5 parts of selenoamino acid and 2-15 parts of remaining active substances. The composition has a strong synergistic effect, constructs an "antioxidation-thrombolysis-lipid-lowering-blood vessel repair" closed loop mechanism, comprehensively covers related pathological links of cardiovascular and cerebrovascular diseases and solves the limitation of single target point intervention.